Quadrature Capital Ltd Acquires 131,995 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Quadrature Capital Ltd raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 736.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 149,908 shares of the pharmaceutical company’s stock after acquiring an additional 131,995 shares during the quarter. Quadrature Capital Ltd owned about 0.06% of Vertex Pharmaceuticals worth $58,695,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Chesapeake Asset Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 33 shares in the last quarter. Colonial Trust Co SC boosted its holdings in Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 38 shares in the last quarter. Total Investment Management Inc. acquired a new position in Vertex Pharmaceuticals during the second quarter worth $33,000. Financial Network Wealth Advisors LLC increased its position in Vertex Pharmaceuticals by 50.9% during the third quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock worth $34,000 after buying an additional 29 shares during the last quarter. Finally, Y.D. More Investments Ltd raised its holdings in Vertex Pharmaceuticals by 345.0% during the third quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 69 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target to $600, signaling meaningful upside from current levels and adding institutional momentum. Oppenheimer Raises Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $600.00
• Positive Sentiment: Bank of America reiterated/issued a bullish view that the stock is positioned to rise, supporting demand from fundamental analysts. Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Bank of America Analyst Says
• Positive Sentiment: Citigroup likewise published a positive forecast for VRTX, adding to the cluster of buy-side endorsements. Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price Expected to Rise, Citigroup Analyst Says
• Positive Sentiment: Morgan Stanley projected strong price appreciation, further cementing a consensus of elevated analyst expectations. Morgan Stanley Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
• Positive Sentiment: Truist raised its price target to $525 and kept a buy rating, another near‑term upside signal from a major sell‑side shop. Benzinga
• Positive Sentiment: News reports show the stock recently spiked (up ~9–10%) on an analyst upgrade, indicating momentum-driven buying can be swift. Vertex Pharmaceuticals (NASDAQ:VRTX) Trading 9.9% Higher on Analyst Upgrade
• Positive Sentiment: Clinical catalyst: a Vertex drug reduced proteinuria in a Phase III IgA nephropathy trial — a meaningful development that could expand the pipeline and long‑term revenue potential. Vertex drug cuts proteinuria in Phase III IgA nephropathy trial
• Neutral Sentiment: Vertex presented at Barclays’ healthcare conference (transcript available) — useful for detail on pipeline timelines and management guidance but not an immediate price mover by itself. Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Coverage note: articles report a rising biotech weighting/focus in Nasdaq indexes, which can support longer‑term passive demand for VRTX but is not an immediate earnings catalyst. Vertex Pharmaceuticals (NASDAQ:VRTX) Biotech Focus Rises In Nasdaq Index
• Negative Sentiment: Despite the bullish notes, the stock has pulled back and printed a larger intraday decline than the market in recent sessions, reflecting profit‑taking and short‑term volatility. Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
• Negative Sentiment: Some commentary flagged that while price moves have been strong, recent earnings‑estimate revision trends may limit near‑term follow‑through. Vertex (VRTX) Moves 8.3% Higher: Will This Strength Last?

Insider Buying and Selling

In other news, EVP Mark E. Bunnage sold 2,021 shares of the firm’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $930,529.03. Following the sale, the executive vice president owned 12,914 shares in the company, valued at approximately $5,945,993.02. This trade represents a 13.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Charles F. Wagner, Jr. sold 9,532 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $461.00, for a total transaction of $4,394,252.00. Following the transaction, the executive vice president directly owned 37,725 shares in the company, valued at $17,391,225. This trade represents a 20.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 91,156 shares of company stock worth $42,845,497. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ:VRTX opened at $478.13 on Friday. The company has a market cap of $121.46 billion, a P/E ratio of 31.19, a P/E/G ratio of 2.10 and a beta of 0.31. The stock’s 50-day moving average is $469.68 and its 200-day moving average is $437.20. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. During the same period in the prior year, the firm posted $3.98 EPS. Vertex Pharmaceuticals’s revenue for the quarter was up 9.5% on a year-over-year basis. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their price target on Vertex Pharmaceuticals from $411.00 to $441.00 and gave the stock a “hold” rating in a research report on Tuesday, February 17th. Morgan Stanley increased their price objective on Vertex Pharmaceuticals from $570.00 to $596.00 and gave the company an “overweight” rating in a report on Tuesday. Truist Financial raised their price objective on Vertex Pharmaceuticals from $490.00 to $525.00 and gave the company a “buy” rating in a research note on Wednesday. Jefferies Financial Group started coverage on Vertex Pharmaceuticals in a report on Tuesday. They issued a “buy” rating and a $580.00 target price for the company. Finally, Stifel Nicolaus upped their target price on Vertex Pharmaceuticals from $445.00 to $466.00 and gave the stock a “hold” rating in a research report on Friday, February 13th. Twenty-three equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $553.36.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.